Eli Lilly Launches Zepbound KwikPen for Obesity Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: PRnewswire
- FDA Approval Expansion: The U.S. FDA has approved a label expansion for Zepbound® to include a four-dose single-patient use KwikPen®, allowing patients to receive a full month of treatment in one device, enhancing medication convenience and choice for patients.
- Transparent Self-Pay Pricing: Patients can access all doses of Zepbound at a self-pay price of $299 through LillyDirect®, ensuring affordability and promoting widespread use of the medication regardless of the delivery method.
- Significant Weight Loss Results: In the SURMOUNT-5 trial, patients using Zepbound lost an average of 50 pounds (20.2%), compared to 33 pounds (13.7%) for those on Wegovy, demonstrating Zepbound's superior efficacy in obesity management and solidifying its market leadership.
- Digital Health Platform Support: In 2025, over 1 million patients accessed treatments through LillyDirect, indicating the platform's success in providing affordable medication access, enhancing patient adherence and satisfaction, and reflecting Eli Lilly's ongoing commitment to supporting individuals with obesity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1009.520
Low
950.00
Averages
1192
High
1500
Current: 1009.520
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Financial Outlook Remains Strong Amid Market Concerns
- Market Resilience: Eli Lilly's leadership in the diabetes medication market allows it to maintain strong financial performance during economic downturns, with analysts predicting that demand for its medicines will remain largely unaffected despite growing concerns over a potential AI bubble burst.
- Innovative Pipeline: Eli Lilly's Zepbound (tirzepatide) leads the weight-loss drug market, and the company is expected to launch new anti-obesity products like orforglipron and retatrutide in the coming years, which will further solidify its market position and drive revenue growth.
- Diversified Development: Beyond its core therapeutic areas, Eli Lilly has a robust pipeline across oncology, immunology, and neuroscience, demonstrating a strategic focus on diversification that enhances its resilience against market fluctuations.
- Dividend Appeal: With a 103.5% increase in dividends over the past five years, Eli Lilly presents an attractive option for dividend-seeking investors, making it a compelling long-term hold even amidst potential market volatility.
See More
Novo Nordisk's Weight Loss Drug Trial Disappoints Investors
- Trial Results: Novo Nordisk's CagriSema drug achieved a 23% average weight loss over 84 weeks, but failed to outperform Eli Lilly's 15mg tirzepatide, which resulted in a 25.5% weight loss, leading to a 14.8% drop in stock price as investors expressed disappointment.
- Participant Details: The trial involved 809 participants suffering from obesity and at least one comorbidity, with an average starting weight of 114.2 kg, indicating CagriSema's effectiveness in weight loss, yet still falling short compared to its competitor's results.
- Future Plans: Despite the underwhelming results, Novo Nordisk remains pleased with the 23% weight loss and intends to proceed with a higher-dose CagriSema trial, reflecting the company's ongoing confidence in the drug's potential.
- Market Outlook: Novo Nordisk has forecasted a 5% to 13% decline in sales and earnings by 2026, and investors had hoped that positive findings from CagriSema would facilitate a quick recovery; however, with the drug's prospects dimming, a rebound may take longer than anticipated.
See More
Analysts Worry AI Bubble May Burst, Eli Lilly's Outlook Remains Positive
- Market Leadership: Eli Lilly has maintained a leading position in the diabetes medication market, with its weight-loss drug Zepbound (tirzepatide) becoming the world's best-selling drug last year, showcasing its strong performance in a rapidly growing market.
- Strong Financial Performance: Despite potential market crashes, Eli Lilly's financial results are expected to remain robust, particularly in the diabetes and weight-loss sectors, with analysts predicting significant expansion in this space over the next decade.
- New Product Pipeline: Eli Lilly plans to launch new anti-obesity products in the coming years, such as orforglipron and retatrutide, which will further solidify its market position and drive revenue growth, even amid increasing competition risks.
- Diversified Development: Beyond diabetes and weight loss, Eli Lilly has a rich pipeline across oncology, immunology, and neuroscience, and is developing an AI supercomputer to accelerate drug development, demonstrating its innovative capabilities and long-term growth potential.
See More
Eli Lilly Launches New Zepbound Weight-Loss Drug
- New Product Launch: Eli Lilly has introduced a new version of its weight-loss drug Zepbound in a KwikPen format, providing a month's supply, which signifies the company's ongoing innovation and expansion in the weight-loss market.
- Pricing Strategy: The new Zepbound KwikPen starts at $299 for cash-paying customers and is available for direct purchase through LillyDirect, aiming to enhance customer purchasing convenience and market penetration.
- Market Reaction: Eli Lilly shares rose nearly 4% in pre-market trading on Monday, indicating a positive market response to the product launch, although retail sentiment on social media remains bearish.
- Market Dynamics: While the product launch has led to a short-term stock price increase, discussions on Stocktwits reflect a cautious sentiment among investors, indicating differing views on the company's future market performance.
See More
Market Dynamics and Investment Strategy Analysis
- Tariff Policy Impact: President Trump raised the global baseline tariff rate from 10% to 15%, which is likely to lead to a down open on Wall Street, potentially affecting investor confidence and exacerbating trade tensions.
- Pharmaceutical Competition: Eli Lilly triumphed over Novo Nordisk in a head-to-head trial, with Novo's obesity drug CagriSema proving less effective than Lilly's Zepbound, resulting in a 15% drop in Novo's shares while Lilly's rose over 3%, indicating increased market confidence in Lilly.
- Banking Sector Upgrade: RBC Capital Markets upgraded Spain's Banco Santander from hold to buy, anticipating that its expansion in the U.S. and upcoming investor day will enhance its market valuation, showcasing its competitive edge in the European banking sector.
- Software Industry Risks: Jefferies downgraded several software companies, citing heightened AI risks and negative sentiment, particularly impacting Workday and DocuSign, indicating a shift in market confidence towards companies like Salesforce that can disrupt themselves.
See More
Eli Lilly Launches New Zepbound Injection Pen for Obesity Treatment
- Product Launch: Eli Lilly has introduced the new Zepbound injection pen, KwikPen, which offers a month's worth of doses in a single device starting at $299 per month, aimed at providing patients with a more convenient medication option and reducing the number of devices needed each month.
- Surging Market Demand: Since its market entry in late 2023, Zepbound has seen explosive demand, generating $4.2 billion in U.S. revenue in the fourth quarter, representing a remarkable 122% year-over-year increase, allowing Eli Lilly to capture a majority share of the weight-loss drug market from rival Novo Nordisk.
- FDA Approval Expansion: The FDA has approved a label expansion for Zepbound to include the multi-dose device, and the introduction of this new form is expected to attract even more patients and drive sales growth.
- Commitment to Patient Support: Ilya Yuffa, President of Lilly USA and Global Customer Capabilities, stated that the KwikPen, trusted by patients globally, reflects the company's commitment to supporting individuals living with obesity in their weight management journey.
See More
Eli Lilly's Financial Outlook Remains Strong Amid Market Concerns
- Market Resilience: Eli Lilly's leadership in the diabetes medication market allows it to maintain strong financial performance during economic downturns, with analysts predicting that demand for its medicines will remain largely unaffected despite growing concerns over a potential AI bubble burst.
- Innovative Pipeline: Eli Lilly's Zepbound (tirzepatide) leads the weight-loss drug market, and the company is expected to launch new anti-obesity products like orforglipron and retatrutide in the coming years, which will further solidify its market position and drive revenue growth.
- Diversified Development: Beyond its core therapeutic areas, Eli Lilly has a robust pipeline across oncology, immunology, and neuroscience, demonstrating a strategic focus on diversification that enhances its resilience against market fluctuations.
- Dividend Appeal: With a 103.5% increase in dividends over the past five years, Eli Lilly presents an attractive option for dividend-seeking investors, making it a compelling long-term hold even amidst potential market volatility.
See More
Novo Nordisk's Weight Loss Drug Trial Disappoints Investors
- Trial Results: Novo Nordisk's CagriSema drug achieved a 23% average weight loss over 84 weeks, but failed to outperform Eli Lilly's 15mg tirzepatide, which resulted in a 25.5% weight loss, leading to a 14.8% drop in stock price as investors expressed disappointment.
- Participant Details: The trial involved 809 participants suffering from obesity and at least one comorbidity, with an average starting weight of 114.2 kg, indicating CagriSema's effectiveness in weight loss, yet still falling short compared to its competitor's results.
- Future Plans: Despite the underwhelming results, Novo Nordisk remains pleased with the 23% weight loss and intends to proceed with a higher-dose CagriSema trial, reflecting the company's ongoing confidence in the drug's potential.
- Market Outlook: Novo Nordisk has forecasted a 5% to 13% decline in sales and earnings by 2026, and investors had hoped that positive findings from CagriSema would facilitate a quick recovery; however, with the drug's prospects dimming, a rebound may take longer than anticipated.
See More
Analysts Worry AI Bubble May Burst, Eli Lilly's Outlook Remains Positive
- Market Leadership: Eli Lilly has maintained a leading position in the diabetes medication market, with its weight-loss drug Zepbound (tirzepatide) becoming the world's best-selling drug last year, showcasing its strong performance in a rapidly growing market.
- Strong Financial Performance: Despite potential market crashes, Eli Lilly's financial results are expected to remain robust, particularly in the diabetes and weight-loss sectors, with analysts predicting significant expansion in this space over the next decade.
- New Product Pipeline: Eli Lilly plans to launch new anti-obesity products in the coming years, such as orforglipron and retatrutide, which will further solidify its market position and drive revenue growth, even amid increasing competition risks.
- Diversified Development: Beyond diabetes and weight loss, Eli Lilly has a rich pipeline across oncology, immunology, and neuroscience, and is developing an AI supercomputer to accelerate drug development, demonstrating its innovative capabilities and long-term growth potential.
See More
Eli Lilly Launches New Zepbound Weight-Loss Drug
- New Product Launch: Eli Lilly has introduced a new version of its weight-loss drug Zepbound in a KwikPen format, providing a month's supply, which signifies the company's ongoing innovation and expansion in the weight-loss market.
- Pricing Strategy: The new Zepbound KwikPen starts at $299 for cash-paying customers and is available for direct purchase through LillyDirect, aiming to enhance customer purchasing convenience and market penetration.
- Market Reaction: Eli Lilly shares rose nearly 4% in pre-market trading on Monday, indicating a positive market response to the product launch, although retail sentiment on social media remains bearish.
- Market Dynamics: While the product launch has led to a short-term stock price increase, discussions on Stocktwits reflect a cautious sentiment among investors, indicating differing views on the company's future market performance.
See More
Market Dynamics and Investment Strategy Analysis
- Tariff Policy Impact: President Trump raised the global baseline tariff rate from 10% to 15%, which is likely to lead to a down open on Wall Street, potentially affecting investor confidence and exacerbating trade tensions.
- Pharmaceutical Competition: Eli Lilly triumphed over Novo Nordisk in a head-to-head trial, with Novo's obesity drug CagriSema proving less effective than Lilly's Zepbound, resulting in a 15% drop in Novo's shares while Lilly's rose over 3%, indicating increased market confidence in Lilly.
- Banking Sector Upgrade: RBC Capital Markets upgraded Spain's Banco Santander from hold to buy, anticipating that its expansion in the U.S. and upcoming investor day will enhance its market valuation, showcasing its competitive edge in the European banking sector.
- Software Industry Risks: Jefferies downgraded several software companies, citing heightened AI risks and negative sentiment, particularly impacting Workday and DocuSign, indicating a shift in market confidence towards companies like Salesforce that can disrupt themselves.
See More
Eli Lilly Launches New Zepbound Injection Pen for Obesity Treatment
- Product Launch: Eli Lilly has introduced the new Zepbound injection pen, KwikPen, which offers a month's worth of doses in a single device starting at $299 per month, aimed at providing patients with a more convenient medication option and reducing the number of devices needed each month.
- Surging Market Demand: Since its market entry in late 2023, Zepbound has seen explosive demand, generating $4.2 billion in U.S. revenue in the fourth quarter, representing a remarkable 122% year-over-year increase, allowing Eli Lilly to capture a majority share of the weight-loss drug market from rival Novo Nordisk.
- FDA Approval Expansion: The FDA has approved a label expansion for Zepbound to include the multi-dose device, and the introduction of this new form is expected to attract even more patients and drive sales growth.
- Commitment to Patient Support: Ilya Yuffa, President of Lilly USA and Global Customer Capabilities, stated that the KwikPen, trusted by patients globally, reflects the company's commitment to supporting individuals living with obesity in their weight management journey.
See More
